Search results

Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

26 August 2009

NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission.

Result type

Technology appraisal guidance

Published

27 October 2010

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

31 January 2018

Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Past technology appraisal appeals and decisions

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

Result type

Technology appraisal guidance

Published

6 September 2017

This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.

Result type

NICE guideline

Published

19 March 2026